Several established treatments exist for cancer and there is currently no indication that fenben will cure cancer or prevent it from returning. There is also no evidence that fenbendazole will prevent recurrence in patients that have already been treated with conventional chemotherapy.

Developing new drugs can be time consuming and expensive. Repurposing veterinary drugs with promising results for human use can reduce the time and costs needed to develop a new drug. Fenbendazole (FZ) is a broad-spectrum benzimidazole anthelmintic that has been used in many animal species as an antiparasitic agent.

Our previous research showed that FZ induces preferential elimination of cancer cells in vitro and in vivo by multiple mechanisms. These include microtubule disruption, stabilization of WT p53 and interference with glucose metabolism. FZ treatment of cancer cells led to a reduction in cell viability and decreased expression of GLUT transporters and hexokinase II, a key glycolytic enzyme that promotes glycolysis.

The purpose of the present study was to investigate how lung cancer patients acquire information about fenbendazole and how they perceive this medication as a treatment for their disease. Twenty-one cancer patients participated in this semi-structured focus group interview. The interviews were conducted from December 7 to 8, 2020, and were supervised by a moderator. The results were analyzed using an inductive thematic analysis. Three major themes emerged: 1) how patients acquired general cancer information; 2) whether the information they obtained was true or false; and 3) their perception toward fenbendazole. fenben cancer treatment